Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab to improve intraoperative slow flow and myocardial injury in NSTEMI PCI
ChiCTR2200058510Phase 4Not yet recruiting
- Sponsor
- Yunnan Fuwai Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of evolocumab in Non-ST-segment elevation myocardial infarction (NSTEMI) and non–ST-segment elevation acute coronary syndrome (NSTE-ACS) (2 arms), sponsored by Yunnan Fuwai Hospital. Primary endpoints: PCSK9 level (proprotein convertase subtilisin/kexin type 9), Low density lipoprotein (LDL) and 7 more. Planned start May 2022; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
Non-ST-segment elevation myocardial infarction (NSTEMI)non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on ChiCTR2200058510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058510.